Dr. Tony Coles, who led Onyx Pharmaceuticals into the waiting arms of Amgen Inc. in a $9.7 billion acquisition, is launching a company focused on discovering drugs for neurodegenerative diseases such as Alzheimer's disease and Lou Gehrig's disease...